丹麦药品巨头Novo Nordisk报告说,Q4销售额上升30%,但预测2025年在竞争中增长放缓。 Danish drug giant Novo Nordisk reports Q4 sales up 30%, but forecasts slower 2025 growth amid competition.

丹麦制药公司诺沃诺迪斯克报告了强的2024年第四季度收益,销售额增长30%至1225亿美元,超过预测. Danish pharmaceutical company Novo Nordisk reported strong Q4 2024 earnings, surpassing forecasts with a 30% sales increase to $12.25 billion. Wegovy销售额翻了一番以上,净利润增加了29%。 Wegovy sales more than doubled, and net profit rose 29%. 2025年,由于竞争加剧和定价压力,公司预测增长放缓16-24%。 For 2025, the company forecasts slower growth of 16-24% due to increased competition and pricing pressure. Novo Nordisk计划在2026年Q1申请CagriSema的条例批准。 Novo Nordisk plans to file for CagriSema's regulatory approval in Q1 2026.